OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
BioNTech plans to expand its global footprint by establishing its regional headquarters for southeast Asia and a new mRNA manufacturing facility in Singapore.
BioNTech announced on May 10, 2021 that it plans to expand its global footprint by establishing its regional headquarters for southeast Asia and a new messenger RNA (mRNA) manufacturing facility in Singapore.
The fully integrated mRNA manufacturing facility will accommodate BioNTech’s pipeline of mRNA-based product candidates and capabilities for rapid response production for southeast Asia’s potential pandemic threats, BioNTech said in a company press release. The new facility, which is set to be operational by 2023, will feature mRNA production capabilities for drug substance, drug product, and fill/finish, and will supply an estimated annual capacity of several hundred million doses of mRNA-based vaccines.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said Ugur Sahin, MD, CEO and co-founder of BioNTech, in the press release. “Singapore provides an excellent business climate, growing biotechnology industry, and rich talent base. We would like to thank Singapore’s Economic Development Board who has been very supportive throughout our planning process and we look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region.”